Bio-Active Semaglutide: How the Active Compound in Wegovy Produces Weight Loss

Step 1: absorption and activation, how semaglutide becomes bio-active in the body

When semaglutide enters the body, either via the weekly subcutaneous injection or the newer oral tablet route, it undergoes a process that converts the delivered dose into its bio-active form: the intact molecule that binds to GLP-1 receptors in the brain, gut and pancreas. For the injection (Wegovy pen), absorption through the subcutaneous tissue is relatively efficient and predictable. For the oral tablet, an absorption enhancer called SNAC is co-formulated with the semaglutide to help the molecule cross the stomach lining before digestive enzymes can break it down.

Once in circulation, semaglutide binds extensively to albumin (a blood protein) which does two things. It protects the molecule from the enzymes that would otherwise degrade it quickly, and it extends its residence in the body to around seven days. That long half-life is precisely what makes once-weekly dosing effective rather than a convenience compromise. The bio-active molecule that reaches GLP-1 receptors is essentially the same structure regardless of route; what differs is the proportion of the dose that gets there. You can read more about the mechanism behind this on our semaglutide action page.

This stability also matters clinically: blood levels rise steadily through the titration schedule, building toward a therapeutic concentration that holds between injections. The dose ladder (starting low and increasing roughly every four weeks) exists to let the body adapt gradually, not because early doses have a different molecular form.

Step 2: receptor binding and the physiological changes that follow

The bio-active semaglutide molecule binds to GLP-1 receptors distributed across several tissues. In the hypothalamus and brainstem, receptor activation reduces appetite signals, so many people find they feel satisfied with less food and experience fewer cravings. In the stomach and upper gut, it slows gastric emptying, meaning food moves through more slowly and fullness lasts longer. In the pancreas, it supports insulin secretion in a glucose-dependent way, relevant for people with type 2 diabetes but also part of the metabolic picture in weight management.

These effects compound over weeks. As the dose increases through the titration schedule, the receptor occupancy rises and the appetite-reducing effect deepens. Clinical evidence reflects this: the effectiveness data for semaglutide comes largely from the STEP trial programme, published in the New England Journal of Medicine, which showed an average reduction of around 15% of body weight at the 2.4 mg maintenance dose over 68 weeks. That figure is an average across thousands of participants, individual results vary, and the evidence is always cited in the context of lifestyle changes alongside treatment.

The MHRA approved a higher 7.2 mg dose in January 2026. Trials at that dose reported roughly 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's clinical trial results. This makes the 7.2 mg option a meaningful development for people who plateaued at 2.4 mg.

Step 3: what the titration schedule means in practice, and why storage affects it

The dose schedule for Wegovy starts at 0.25 mg and increases in steps prescribed by your clinician, typically reaching 2.4 mg as the standard maintenance dose, with 7.2 mg now available for eligible patients. Each step is held for roughly four weeks to allow the body to adjust and for any gastrointestinal side effects (nausea, loose stools, reduced appetite early in a new dose) to settle. These effects are a direct consequence of the bio-active molecule's action on gut motility; they are expected, not a sign that treatment is wrong.

Storing the pen correctly is essential to keeping the semaglutide molecule intact. Wegovy pens are stored in the fridge at 2–8°C (many people keep theirs in the fridge door so it's easy to remember on injection day) and should not be frozen. The Patient Information Leaflet sets out the exact rules for room-temperature storage if refrigeration is temporarily unavailable; always follow the leaflet rather than general advice, because the permitted window is specific. A damaged or improperly stored pen may deliver degraded rather than fully bio-active semaglutide, which is one reason Wegovy should only be sourced through a regulated supply chain.

If you are weighing up whether semaglutide is the right option for your situation, our weight-loss treatment overview sets out the licensed options clearly. Pricing context for semaglutide-based treatment is covered on our Wegovy cost page, which explains what a legitimate private prescription includes.

Who the licensed eligibility criteria cover, and what happens at consultation

Bio-active semaglutide's clinical effects were studied in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, high cholesterol or obstructive sleep apnoea. The UK licence for Wegovy reflects those populations. Lower BMI thresholds can apply for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance.

Meeting a BMI figure is a starting point, not a guarantee. A GPhC-registered Independent Prescriber reviews the full clinical picture (your medical history, current medicines, any contraindications) before approving treatment. That review matters: semaglutide is not suitable in pregnancy, is not recommended during breastfeeding, and should not be started while trying to conceive. People with a history of certain thyroid conditions or pancreatitis need particular care. If you are based in or near Chilton, you can find localised guidance on our Chilton semaglutide page, which covers how to access treatment in that area. The most effective dose for semaglutide is also an individual question, not a universal answer.

At nume, every consultation is read by a real clinician, the kind of question our prescribers hear regularly is whether a person's existing medicines might interact with semaglutide. If you would like to speak to someone directly, the contact page has the details. Side effects should be reported via the MHRA Yellow Card scheme, and the NHS semaglutide medicine page is a reliable reference for what to watch for. When you are ready, check your eligibility with our clinical team.